Kalamazoo Resources Ltd
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 58
- Market Cap
- $46.4M
- Introduction
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE)
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT05781750
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸Southwest Kidney Institute, Surprise, Arizona, United States
🇺🇸Valerius Medical Group and Research Center of Greater Long Beach, Inc., Los Alamitos, California, United States
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
- Conditions
- Autoimmune Hepatitis
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05569759
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Keck School of Medicine of USC, Los Angeles, California, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
KZR-261 in Subjects With Advanced Solid Malignancies
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05047536
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04628936
- Locations
- 🇨🇿
KZR Research Site, Prague, Czechia
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
- Conditions
- Immune ThrombocytopeniaAutoimmune Hemolytic Anemia
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Registration Number
- NCT04039477
- Locations
- 🇷🇺
KZR Research Site, Saint Petersburg, Russian Federation
🇺🇸KZR-616 Research Site, Rochester, Minnesota, United States
- Prev
- 1
- 2
- Next